Reversed binding of a small molecule ligand in homologous chemokine receptors - Differential role of extracellular loop 2

British Journal of Pharmacology

Volumn 166, Issue 1, 2012, Pages 258-275

  Jensen, P C ^a   Thiele, S ^a   Steen, A ^a   Elder, A ^b,c   Kolbeck, R ^b,e   Ghosh, S ^b,d   Frimurer, T M ^a   Rosenkilde, Mette M ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

^c Galenea Corporation   (United States)

^d Pharmaceuticals Inc   (United States)

^e MEDIMMUNE   (United States)

Author keywords

chemokine receptors; extracellular loop 2; reversed binding; small molecule agonist

Indexed keywords

1 [3 (2 CHLOROPHENOXY)BENZYL] 4 [5 CHLORO 2 (1H TETRAZOL 5 YL)PHENYL]PIPERIDIN 4 OL; ALANINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR8; GLUTAMIC ACID; INOSITOL TRISPHOSPHATE; LYSINE; PIPERIDINE DERIVATIVE; PROLINE; TRIPHENYLTETRAZOLIUM; TYROSINE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; BINDING SITE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; EXTRACELLULAR MATRIX; MOLECULAR MODEL; MUTATIONAL ANALYSIS; PHARMACOPHORE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; STRUCTURAL HOMOLOGY; STRUCTURE ANALYSIS;

ANIMALS; BINDING SITES; CERCOPITHECUS AETHIOPS; COS CELLS; GLUTAMIC ACID; HUMANS; INOSITOL 1,4,5-TRISPHOSPHATE; LIGANDS; MODELS, MOLECULAR; PIPERIDINES; POINT MUTATION; RECEPTORS, CCR1; RECEPTORS, CCR8; TETRAZOLES;

EID: 84859730971     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01771.x     Document Type: Article

References (71)

1. Alexander SPH, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th Edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
2. Allen SJ, Crown SE, Handel TM, (2007). Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol 25: 787-820.
3. Arias DA, Navenot JM, Zhang WB, Broach J, Peiper SC, (2003). Constitutive activation of CCR5 and CCR2 induced by conformational changes in the conserved TXP motif in transmembrane helix 2. J Biol Chem 278: 36513-36521.
4. Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada H, Iizawa Y, et al,. (1999). A small molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci U S A 96: 5698-5703.
5. Baldwin JM, (1993). The probable arrangement of the helices in G protein-coupled receptors. EMBO J 12: 1693-1703.
6. Ballesteros JA, Weinstein H, (1995). Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. Receptor Molecular Biology 25: 366-428.
7. Barth P, Wallner B, Baker D, (2009). Prediction of membrane protein structures with complex topologies using limited constraints. Proc Natl Acad Sci U S A 106: 1409-1414.
8. Benned-Jensen T, Rosenkilde MM, (2008). Structural motifs of importance for the constitutive activity of the orphan 7TM receptor EBI2: analysis of receptor activation in the absence of an agonist. Mol Pharmacol 74: 1008-1021.
9. Benned-Jensen T, Rosenkilde MM, (2009). The role of transmembrane segment II in 7TM receptor activation. Curr Mol Pharmacol 2: 140-148.
10. Berkhout TA, Blaney FE, Bridges AM, Cooper DG, Forbes IT, Gribble AD, et al,. (2003). CCR2: characterization of the antagonist binding site from a combined receptor modeling/mutagenesis approach. J Med Chem 46: 4070-4086.
11. Black JW, Leff P, (1983). Operational models of pharmacological agonism. Proc R Soc Lond 220: 141-162.
12. Bottegoni G, Kufareva I, Totrov M, Abagyan R, (2009). Four-dimensional docking: a fast and accurate account of discrete receptor flexibility in ligand docking. J Med Chem 52: 397-406.
13. Bouvier M, Hnatowitch M, Collins SK, Kobilka B, Deblasi A, Lefkowitz RJ, et al,. (1988). Expression of a human cDNA encoding the b2-adrenergic receptor in Chinese hamster fibroblasts (CHW): functionality and regulation of the expressed receptors. Mol Pharmacol 33: 133-139.
14. Canutescu AA, Dunbrack RL, (2003). Cyclic coordinate descent: a robotics algorithm for protein loop closure. Protein Sci 12: 963-972.
15. Castonguay LA, Weng Y, Adolfsen W, Di Salvo J, Kilburn R, Caldwell CG, et al,. (2003). Binding of 2-aryl-4-(piperidin-1-yl)butanamines and 1.3,4-trisubstituted pyrrolidines to human CCR5: a molecular modeling-guided mutagenesis study of the binding pocket. Biochemistry 42: 1544-1550.
16. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, et al,. (2007). High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 318: 1258-1265.
17. Coutsias EA, Seok C, Wester MJ, Dill KA, (2005). Resultants and loop closure. Int J Quantum Chem 1: 176-189.
18. Elling CE, Schwartz TW, (1996). Connectivity and orientation of the seven helical bundle in the tachykinin NK-1 receptor probed by zinc site engineering. EMBO J 15: 6213-6219.
19. Farrens DL, Altenbach C, Yang K, Hubbell WL, Khorana HG, (1996). Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. Science 274: 768-770.
20. Gao P, Zhou XY, Yashiro-Ohtani Y, Yang YF, Sugimoto N, Ono S, et al,. (2003). The unique target specificity of a nonpeptide chemokine receptor antagonist: selective blockade of two Th1 chemokine receptors CCR5 and CXCR3. J Leukoc Biol 73: 273-280.
21. Gombert M, eu-Nosjean MC, Winterberg F, Bunemann E, Kubitza RC, Da Cunha L, et al,. (2005). CCL1-CCR8 interactions: an axis mediating the recruitment of t cells and langerhans-type dendritic cells to sites of atopic skin inflammation. J Immunol 174: 5082-5091.
22. Govaerts C, Blanpain C, Deupi X, Ballet S, Ballesteros JA, Wodak SJ, et al,. (2001). The TXP motif in the second transmembrane helix of CCR5. A structural determinant of chemokine-induced activation. J Biol Chem 276: 13217-13225.
23. Hall SE, Mao A, Nicolaidou V, Finelli M, Wise EL, Nedjai B, et al,. (2009). Elucidation of binding sites of dual antagonists in the human chemokine receptors CCR2 and CCR5. Mol Pharmacol 75: 1325-1336.
24. Haskell CA, Horuk R, Liang M, Rosser M, Dunning L, Islam I, et al,. (2006). Identification and characterization of a potent, selective nonpeptide agonist of the CC chemokine receptor CCR8. Mol Pharmacol 69: 309-316.
25. Hesselgesser J, Howard PN, Liang M, Zheng W, May K, Bauman JG, et al,. (1998). Identification and characterization of small molecule functional antagonists of the CCR1 chemokine receptor. J Biol Chem 273: 15687-15692.
26. Heydorn A, Ward RJ, Jorgensen R, Rosenkilde MM, Frimurer TM, Milligan G, et al,. (2004). Identification of a novel site within G protein alpha subunits important for specificity of receptor-G protein interaction. Mol Pharmacol 66: 250-259.
27. Hubbell WL, Altenbach C, Hubbell CM, Khorana HG, (2003). Rhodopsin structure, dynamics, and activation: a perspective from crystallography, site-directed spin labeling, sulfhydryl reactivity, and disulfide cross-linking. Adv Protein Chem 63: 243-290.
28. Jaakola VP, Griffith MT, Hanson MA, Cherezov V, Chien EY, Lane JR, et al,. (2008). The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 322: 1211-1217.
29. Jenkins TJ, Guan B, Dai M, Li G, Lightburn TE, Huang S, et al,. (2007). Design, synthesis, and evaluation of naphthalene-sulfonamide antagonists of human CCR8. J Med Chem 50: 566-584.
30. Jensen PC, Rosenkilde MM, (2009). Chapter 8. Activation mechanisms of chemokine receptors. Methods Enzymol 461: 171-190.
31. Jensen PC, Nygaard R, Thiele S, Elder A, Zhu G, Kolbeck R, et al,. (2007). Molecular interaction of a potent nonpeptide agonist with the chemokine receptor CCR8. Mol Pharmacol 72: 327-340.
32. Jensen PC, Thiele S, Ulven T, Schwartz TW, Rosenkilde MM, (2008). Positive versus negative modulation of different endogenous chemokines for CC-chemokine receptor 1 by small molecule agonists through allosteric versus orthosteric binding. J Biol Chem 283: 23121-23128.
33. Johnson GL, Bourne HR, Gleason MK, Coffino P, Insel PA, Melmon KL, (1979). Isolation and characterization of S49 lymphoma cells deficient in b-adrenergic receptors:relation of receptor number to activation of adenylate cyclase. Mol Pharmacol 15: 16-27.
34. Kledal TN, Rosenkilde MM, Coulin F, Simmons G, Johnsen AH, Alouani S, et al,. (1997). A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science 277: 1656-1659.
35. Liang M, Mallari C, Rosser M, Ng HP, May K, Monahan S, et al,. (2000). Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1. J Biol Chem 275: 19000-19008.
36. Luttichau HR, Stine J, Boesen TP, Johnsen AH, Chantry D, Gerstoft J, et al,. (2000). A highly selective CC chemokine receptor (CCR)8 antagonist encoded by the poxvirus molluscum contagiosum. J Exp Med 191: 171-180.
37. Maeda K, Das D, Ogata-Aoki H, Nakata H, Miyakawa T, Tojo Y, et al,. (2006). Structural and molecular interactions of CCR5 inhibitors with CCR5. J Biol Chem 281: 12688-12698.
38. Mandell DJ, Coutsias EA, Kortemme T, (2009). Sub-angstrom accuracy in protein loop reconstruction by robotics-inspired conformational sampling. Nat Methods 6: 551-552.
39. de Mendonca FL, da Fonseca PC, Phillips RM, Saldanha JW, Williams TJ, Pease JE, (2005). Site-directed mutagenesis of CC chemokine receptor 1 reveals the mechanism of action of UCB 35625, a small molecule chemokine receptor antagonist. J Biol Chem 280: 4808-4816.
40. Mirzadegan T, Diehl F, Ebi B, Bhakta S, Polsky I, McCarley D, et al,. (2000). Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists: binding to a common chemokine receptor motif within the helical bundle. J Biol Chem 275: 25562-25571.
41. Mirzadegan T, Benko G, Filipek S, Palczewski K, (2003). Sequence analyses of G-protein-coupled receptors: similarities to rhodopsin. Biochemistry 42: 2759-2767.
42. Mizuguchi K, Deane CM, Blundell TL, Overington JP, (1998). HOMSTRAD: a database of protein structure alignments for homologous families. Protein Sci 7: 2469-2471.
43. Murphy PM, Baggiolini M, Charo IF, Hebert CA, Horuk R, Matsushima K, et al,. (2000). International union of pharmacology. XXII Nomenclature for chemokine receptors. Pharmacol Rev 52: 145-176.
44. Nygaard R, Frimurer TM, Holst B, Rosenkilde MM, Schwartz TW, (2009). Ligand binding and micro-switches in 7TM receptor structures. Trends Pharmacol Sci 30: 249-259.
45. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, et al,. (2000). Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289: 739-745.
46. Patel L, Charlton SJ, Chambers JK, Macphee CH, (2001). Expression and functional analysis of chemokine receptors in human peripheral blood leukocyte populations. Cytokine 14: 27-36.
47. Peeters MC, van Westen GJ, Li Q, Ijzerman AP, (2011). Importance of the extracellular loops in G protein-coupled receptors for ligand recognition and receptor activation. Trends Pharmacol Sci 32: 35-42.
48. Phillips R, Lutz M, Premack B, (2005). Differential signaling mechanisms regulate expression of CC chemokine receptor-2 during monocyte maturation. J Inflamm 2: 14.
49. Rasmussen SGF, Choi HJ, Fung JJ, Pardon E, Casarosa P, Chae PS, et al,. (2011). Structure of a nanobody-stabilized active state of the [bgr]2 adrenoceptor. Nature 469: 175-180.
50. Rosenbaum DM, Cherezov V, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, et al,. (2007). GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science 318: 1266-1273.
51. Rosenkilde MM, Schwartz TW, (2006). GluVII:06-a highly conserved and selective anchor point for non-peptide ligands in chemokine receptors. Curr Top Med Chem 6: 1319-1333.
52. Rosenkilde MM, Cahir M, Gether U, Hjorth SA, Schwartz TW, (1994). Mutations along transmembrane segment II of the NK-1 receptor affect substance P competition with non-peptide antagonists but not substance P binding. J Biol Chem 269: 28160-28164.
53. Rosenkilde MM, Benned-Jensen T, Frimurer TM, Schwartz TW, (2010). The minor binding pocket-a major player in 7TM receptor activation. Trends Pharmacol Sci 12: 567-574.
54. Sabroe I, Peck MJ, Van Keulen BJ, Jorritsma A, Simmons G, Clapham PR, et al,. (2000). A small molecule antagonist of chemokine receptors CCR1 and CCR3. Potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry. J Biol Chem 275: 25985-25992.
55. Scheerer P, Park JH, Hildebrand PW, Kim YJ, Krausz N, Choe HW, et al,. (2008). Crystal structure of opsin in its G-protein-interacting conformation. Nature 455: 497-502.
56. Schwartz TW, (1994). Locating ligand-binding sites in 7TM receptors by protein engineering. Curr Opin Biotechnol 5: 434-444.
57. Schwartz TW, Rosenkilde MM, (1996). Is there a 'lock' for all 'keys' in 7TM receptors. Trends Pharmacol Sci 17: 213-216.
58. Schwarz MK, Wells TN, (2002). New therapeutics that modulate chemokine networks. Nat Rev Drug Discov 1: 347-358.
59. Seibert C, Ying W, Gavrilov S, Tsamis F, Kuhmann SE, Palani A, et al,. (2006). Interaction of small molecule inhibitors of HIV-1 entry with CCR5. Virology 349: 41-54.
60. Shi J, Blundell TL, Mizuguchi K, (2001). FUGUE: sequence-structure homology recognition using environment-specific substitution tables and structure-dependent gap penalties. J Mol Biol 310: 243-257.
61. Strader CD, Sigal IS, Register RB, Candelore MR, Rands E, Dixon RA, (1987). Identification of residues required for ligand binding to the beta-adrenergic receptor. Proc Natl Acad Sci U S A 84: 4384-4388.
62. Totrov M, Abagyan R, (2008). Flexible ligand docking to multiple receptor conformations: a practical alternative. Curr Opin Struct Biol 18: 178-184.
63. Tsamis F, Gavrilov S, Kajumo F, Seibert C, Kuhmann S, Ketas T, et al,. (2003). Analysis of the mechanism by which the small molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J Virol 77: 5201-5208.
64. Vaidehi N, Schlyer S, Trabanino RJ, Floriano WB, Abrol R, Sharma S, et al,. (2006). Predictions of CCR1 chemokine receptor structure and bx 471 antagonist binding followed by experimental validation. J Biol Chem 281: 27613-27620.
65. Wang C, Bradley P, Baker D, (2007). Protein-protein docking with backbone flexibility. J Mol Biol 373: 503-519.
66. Warne T, Serrano-Vega MJ, Baker JG, Moukhametzianov R, Edwards PC, Henderson R, et al,. (2008). Structure of a [bgr]1-adrenergic G-protein-coupled receptor. Nature 454: 486-491.
67. Warne T, Moukhametzianov R, Baker JG, Nehme R, Edwards PC, Leslie AGW, et al,. (2011). The structural basis for agonist and partial agonist action on a [bgr]1-adrenergic receptor. Nature 469: 241-244.
68. Wells TN, Power CA, Shaw JP, Proudfoot AE, (2006). Chemokine blockers-therapeutics in the making? Trends Pharmacol Sci 27: 41-47.
69. Williams MG, Shirai H, Nagendra JHG, Mueller J, Mizuguchi K, Miguel RH, et al,. (2001). Sequence-structure homology recognition by iterative alignment refinement and comparative modeling. Proteins (Suppl. 5): 92-97.
70. Wu B, Chien EY, Mol CD, Fenalti G, Liu W, Katritch V, et al,. (2010). Structures of the CXCR4 chemokine GPCR with small molecule and cyclic peptide antagonists. Science 330: 1066-1071.
71. Zingoni A, Soto H, Hedrick JA, Stoppacciaro A, Storlazzi JA, Sinigaglia F, et al,. (1998). Cutting edge: the chemokine receptor CCR8 is preferentially expressed in Th2 but not Th1 cells1.2. J Immunol 161: 547-551.